First genome-wide association study on rocuronium dose requirements shows association with SLCO1A2 by Ahlström, Sirkku et al.
British Journal of Anaesthesia, 126 (5): 949e957 (2021)
doi: 10.1016/j.bja.2021.01.029
Advance Access Publication Date: 4 March 2021
Clinical PracticeFirst genome-wide association study on rocuronium dose
requirements shows association with SLCO1A2
Sirkku Ahlstr€om1,*, Paula Bergman2, Ritva Jokela1, Linda Ottensmann3, Ari Ahola-Olli3,
Matti Pirinen3,4,5, Klaus T. Olkkola1, Mari A. Kaunisto3,y and Eija Kalso1,6,7,y
1Department of Anaesthesiology, Intensive Care and Pain Medicine, University of Helsinki and HUS Helsinki University
Hospital, Helsinki, Finland, 2Biostatistics Consulting, Department of Public Health, University of Helsinki and HUS
Helsinki University Hospital, Helsinki, Finland, 3Institute for Molecular Medicine Finland, Helsinki Institute of Life
Science, University of Helsinki, Helsinki, Finland, 4Helsinki Institute for Information Technology and Department of
Mathematics and Statistics, University of Helsinki, Helsinki, Finland, 5Department of Public Health, University of
Helsinki, Helsinki, Finland, 6Department of Pharmacology, Faculty of Medicine, University of Helsinki, Helsinki, Finland
and 7SleepWell Research Programme, Faculty of Medicine, University of Helsinki, Helsinki, Finland
*Corresponding author. E-mail: Sirkku.tornqvist@helsinki.fi
yThese authors contributed equally.Abstract
Background: Rocuronium, a common neuromuscular blocking agent, is mainly excreted unchanged in urine (10e25%)
and bile (>70%). Age, sex, liver blood flow, smoking, medical conditions, and ethnic background can affect its pharma-
cological actions. However, reasons for the wide variation in rocuronium requirements are mostly unknown. We
hypothesised that pharmacogenetic factors might explain part of the variation.
Methods: One thousand women undergoing surgery for breast cancer were studied. Anaesthesia was maintained with
propofol (50e100 mg kg1 min1) and remifentanil (0.05e0.25 mg kg1 min1). Neuromuscular block was maintained with
rocuronium to keep the train-of-four ratio at 0e10%. DNA was extracted from peripheral blood and genotyped with a
next-generation genotyping array. The genome-wide association study (GWAS) was conducted using an additive linear
regression model with PLINK software. The FINEMAP tool and data from the Genotype-Tissue Expression project v8 were
utilised to study the locus further.
Results: The final patient population comprised 918 individuals. Of the clinical variables tested, age, BMI, ASA physical
status, and total dose of propofol correlated significantly (all P<0.001) with the rocuronium dose in a linear regression
model. The GWAS highlighted one genome-wide significant locus in chromosome 12. The single-nucleotide poly-
morphisms (SNPs) with the most significant evidence of association were located in or near SLCO1A2. The two top SNPs,
rs7967354 (P¼5.3e11) and rs11045995 (P¼1.4e10), and the clinical variables accounted for 41% of the variability in
rocuronium dosage.
Conclusions: Genetic variation in the gene SLCO1A2, encoding OATP1A2, an uptake transporter, accounted for 4% of the
variability in rocuronium consumption. The underlying mechanism remains unknown.
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 There is considerable inter-individual variability in
patient requirements for rocuronium, a drug that is
mainly excreted unchanged in the bile.
 The authors performed a genome-wide association
study in a large cohort of women undergoing breast
cancer surgery.
 Genetic variation in the gene SLCO1A2, which encodes
OATP1A2, an uptake transporter for which rocuronium
is a substrate, explained 4% of the variability in
rocuronium requirements.
 Clinical variables, such as age, BMI, ASA physical sta-
tus, and total dose of propofol, explained a much larger
portion of the inter-individual variability.Rocuronium bromide is a commonly used amino-steroidal
non-depolarising neuromuscular blocking drug that competi-
tively binds to post-junctional nicotinic acetylcholine re-
ceptors in the neuromuscular junction, blocking the action of
acetylcholine and thereby inhibiting the contraction of striatal
muscles.
Rocuronium is mainly excreted unchanged in urine
(10e25%) and bile (more than 70%).1,2 Both renal and hepatic
insufficiencies decrease clearance and prolong its action.3,4
Based on in vitro studies with animal and human liver tissue,
rocuronium is a substrate for organic anion transporters
(OATPs). The transporters take up rocuronium in the liver.5,6
Rocuronium is not generally considered to be metabolised in
the liver, although there are conflicting views (https://www.
clinicalkey.com/#!/content/6-s2.0-552). Rocuronium is a high-
ly hydrophilic molecule and binds poorly (about 25%) to
plasma proteins.7
Several reports have demonstrated major inter-individual
differences in the duration of action of rocuronium.8e11
Advanced age,12 female sex,13 conditions and treatments
that alter the skeletal muscle acetylcholine receptors,14
decrease in hepatic blood flow during surgery,15 smoking,16
and ethnic background17e19 can also affect the pharmacoki-
netics or pharmacodynamics of rocuronium.
We hypothesised that pharmacogenetic factors might
explain part of the unaccounted variation in the pharmaco-
logical response to rocuronium. The aim of this study was to
identify genetic factors associated with the requirements of
rocuronium by performing the first-ever genome-wide asso-
ciation study (GWAS) in a large cohort of women undergoing
breast cancer surgery.Methods
BrePainGen is a prospective study designed to examine the
role of genetics in acute and persistent post-surgical pain,
mood, and effects of drugs used in anaesthesia. One thousand
women undergoing surgery for breast cancer at the Helsinki
University Hospital were recruited between August 1, 2006 and
December 31, 2010. The study protocol was approved by the
coordinating ethics committee (136/E0/2006) and the ethics
committee of the Department of Surgery (Dnro 148/E6/05) of
the Hospital District of Helsinki and Uusimaa. Written
informed consent was obtained from all patients. A flow chart
of patient recruitment is provided in Supplementary Fig. 1.
After informed consent, the patients were interviewed for
background information about medical conditions,medications, age, height, weight, previous operations, use of
alcohol, and smoking. Those using drugs affecting the phar-
macology of rocuronium were excluded.
All patients were premedicated with diazepam 2.5e15 mg
and paracetamol 1 g orally. Anaesthesia was induced with
propofol 2e3mg kg1, and remifentanil infusion of 0.2mg kg1
min1 was started. Tracheal intubation was facilitated with
rocuronium 0.6 mg kg1. During surgery, anaesthesia was
maintained with a propofol infusion at 50e100 mg kg1 min1
to keep state entropy (M-Entropy S/5TMModule for Anesthesia
Monitor; GE Healthcare Finland, Helsinki, Finland) at the level
of 50 [5]. Remifentanil infusion was used at 0.05e0.25 mg kg1
min1 to keep systolic BP at [15%] of baseline minus 20mmHg.
The neuromuscular block was maintained throughout the
surgery with rocuronium boluses of 10mg to keep the train-of-
four ratio at 0e10% (E-NMT; GE Healthcare Finland). Mechan-
ical ventilation was adjusted to normocapnia with 1:1 oxygen
and nitrous oxide. During closure of the skin, remifentanil
infusion was stopped, and boluses of fentanyl 1 mg kg1,
ondansetron 4 mg, and droperidol 0.01 mg kg1 were given
intravenously. Neuromuscular block was reversed with
neostigmine 2.5 mg and glycopyrrolate 0.5 mg. Before the pa-
tient woke from anaesthesia, a blood specimen was drawn for
DNA isolation.
DNA was extracted from peripheral blood using the Auto-
pure LS™ automated DNA purification instrument (Gentra
Systems, Inc., Minneapolis, MN, USA). Genotype data were
produced at the Wellcome Sanger Institute (Hinxton, UK) on
the HumanOmniExpress Illumina BeadChip (Illumina, Inc.,
San Diego, CA, USA) while blind to phenotypic information.
Sample quality control procedures have been described in
detail earlier.20 All single-nucleotide polymorphisms (SNPs)
were filtered based on minor allele frequency (MAF >0.0005),
HardyeWeinberg equilibrium (P>1  106), and success rate
(>0.97). The mean genotyping success rate was 0.997. After
quality control, genotyping data were available for 926 of the
1000 participants. Eight patients were excluded for clinical
reasons. The final participant population comprised 918 in-
dividuals with both genotype and clinical data available
(Tables 1 and 2).
Statistical analyses and data management were conducted
using IBM SPSS software versions 23.0 and 24.0 and R version
3.6.2 (R Foundation for Statistical Computing, Vienna, Austria).
To identify possible confounders that should be taken into
account when performing the GWAS, we first performed uni-
variate testing (n¼992) between clinical variables and the dose
of rocuronium needed to maintain adequate neuromuscular
block. We took the dose rates of rocuronium (in units of mg
kg1 min1) using the natural logarithms of their numerical
values to ensure normal distribution. The clinical variables to
be tested for relevance to rocuronium dose requirements were
age, height, BMI, total use of propofol during anaesthesia (mg
kg1 min1), total use of remifentanil during anaesthesia (mg
kg1 min1), ASA class, smoking (yes/no), alcohol use (yes/
abstinent), type of axillary surgery (sentinel node biopsy/
evacuation), and breast surgery (resection/mastectomy). We
also tested associations between CYP2D6 copy numbers,
CYP2D6-predicted phenotype (poor, intermediate, extensive,
or ultra-rapid metabolisers), CYP3A4 variant rs35599367 ge-
notype (CC/CT/TT) and CYP3A5 variant rs776746 genotype (GG/
AG/AA), and the natural logarithm of rocuronium dose rates
(expressed in mg kg1 min1), as the CYP data were available
from these patients.21 We tested these associations using t-
test, ManneWhitney U-test, analysis of variance, or
Table 2 Characteristics of the patients, anaesthesia, and total
dose of rocuronium; n¼918.
Median (inter-
quartile range)
Age (yr) 58 (50e64)
Height (cm) 164 (160e169)
Weight (kg) 68 (60e76)
BMI (kg m-2) 24.8 (22.3e28.2)
Total dose of rocuronium (mg) 75 (60e90)
Time to first additional dose after
induction (min)
38 (30e46)
Time to recovery after last dose (min) 47 (38e57)
Duration of anaesthesia (min) 138 (115e168)
Dose of rocuronium (mg kg1 min1) 7.9 (6.5e9.7)
Total dose of remifentanil during
anaesthesia (mg)
0.8 (0.6e1.1)
Dose of remifentanil (mg kg1 min1) 0.008 (0.007
e0.010)
Total dose of propofol during
anaesthesia (mg)
897 (718e1102)
Dose of propofol (mg kg1 min1) 95 (83e110)
Table 1 Characteristics of the subjects. n¼992 for all included
in the association testing, and n¼918 for genetic testing based






1 5.6 (56) 5.4 (50)
2 82.5 (818) 82.8 (760)
3 11.9 (118) 11.8 (108)
Type of surgery
in the axilla
Sentinel node biopsy 55.8 (554) 55 (505)
Evacuation of axilla 44.2 (438) 45 (413)
Type of surgery in
the breast
Resection 62.4 (619) 62.2 (571)
Mastectomy 37.6 (373) 37.8 (347)
Smoking habits
No 82 (813) 82.5 (757)
Yes 18 (179) 17.5 (161)
Alcohol use
No 17.5 (173) 18.1 (166)
Yes 82.5 (819) 81.9 (752)
SLCO1A2 and rocuronium dose requirements - 951KruskaleWallis test, depending on the distributions of vari-
ables. Pairwise comparisons were adjusted with Bonferroni
corrections.
After studying possible associations, we conducted multi-
variate linear regression modelling based on variables that
had statistically significant (P<0.05) associations with rocuro-
nium requirements. We used a stepwise method to construct
the final model. The final linear regression model contained
only variables that remained significant in multivariate
testing. These were used as covariates in the GWAS. In addi-
tion, the first five dimensions from multidimensional scaling
of genotype data were also used as covariates to take into
account a possible hidden population structure.The GWAS was conducted using an additive linear regres-
sion model with PLINK software.22 Associations between total
dose of rocuronium and 653 034 genetic variants (SNPs) were
tested. The standard threshold of genome-wide statistical
significance, P<5 108, was used. After GWAS results became
available, we performed another linear regression round,
including four lead variants, to examine the impact of these on
the total dose of rocuronium.
The genomic region showing a significant association with
rocuronium dosage was further examined to identify the most
likely causal SNPs within the locus. For this, the genomic data
were first pre-phased with Eagle software version 2.4.23 Sub-
sequently, the genotypes were imputed using Beagle 4.1 and
population-specific Sequencing Initiative Suomi panel as
imputation reference.24,25 Poorly imputed variants were
excluded (INFO <0.7). The imputation reference panel con-
sisted of 3775 Finns. To identify the number of independent
association signals and the lead SNPs within the associated
locus, the FINEMAP26 tool was used. The FUMA27 tool was used
to examine the potential functional effect of each associated
SNP. Genetic effects on gene expression across tissue types
were studied using publicly available data from the Genotype-
Tissue Expression project v8.28 FINEMAP 1.426 was run,
allowing amaximum of K¼5 causal variants. The credible sets,
those containing the most likely causal variants, were re-
ported, assuming either one or two causal variants.Results
To test associations with clinical variables, all 992 individuals
with complete clinical data were used. For 918 of these,
genome-wide genotype data were available and used for the
GWAS. The characteristics of the subjects and of rocuronium
requirements are shown in Tables 1 and 2. The total dose of
rocuronium had a linear relationship (R2¼0.412) with the
duration of anaesthesia (Fig. 1a). The median number of
additional doses was 4 (inter-quartile range [IQR]: 2e5), range
0e20. Twenty-one patients did not receive additional doses of
rocuronium after intubation.
Of the continuous variables tested, age (P<0.001), BMI
(P<0.001), and total doses of propofol (mg kg1 min1; P<0.001)
and of remifentanil (mg kg1 min1; P<0.001) had significant
correlations with the dose of rocuronium (in mg kg1 min1).
Of the dichotomous and ordinal variables, ASA class (P<0.001),
use of alcohol compared with abstinence (P¼0.001), and breast
resection vs mastectomy (P<0.001) were statistically signifi-
cant at P<0.05.
Multiple linear regression models were run to understand
the effects of the aforementioned variables on the dose of
rocuronium (in mg kg1 min1). There was homoscedasticity
as assessed by visual inspection of a plot of standardised re-
siduals vs standardised predicted values, normality of the re-
siduals being assessed by visual inspection of a normal
probability plot: there were no significant outliers, as assessed
by Cook’s distance. The results of the linear model are pre-
sented in Table 3. The clinical variables in the model accoun-
ted for 35.3% of the variability in rocuronium dosage.
The GWAS highlighted one locus on chromosome 12
showing genome-wide significant evidence of association
with rocuronium dose (Fig. 2). Eight genotyped SNPs reached
the standard threshold of genome-wide statistical signifi-
cance, P<5  108 (Table 4). The SNPs with the most signifi-
cant evidence of association were all located in or near gene


















































































Fig 1. Relationship between rocuronium dose and (a) duration of anaesthesia and (bed) the two lead SNPs showing genome-wide sig-
nificant association with rocuronium dose in the GWAS. (a) Rocuronium requirements of the study participants plotted against the
duration of anaesthesia. Patients homozygous for the minor alleles of both of the lead SNPs (rs7967354-G and rs11045995-G) are high-
lighted in blue. Mean rocuronium dosage in this group is lower than the average, and the individual data points are also clearly at the lower
end of the requirement distribution. (b) Box and whisker plot showing rocuronium requirements during anaesthesia classified by
rs7967354 genotype. The middle line of the box represents median, and the upper and lower edges of the box represent upper and lower
quartiles, respectively. Upper whisker represents the minimum between the maximum value and the upper quartileþ1.5 * inter-quartile
range. Lower whisker represents the maximum between the minimum value and the lower quartilee1.5 * inter-quartile range. Any values
outside the whiskers are outliers, presented as circles. (c) Box and whisker plot showing the rocuronium requirements during anaesthesia
according to rs11045995 genotype. (d) Box and whisker plot showing rocuronium requirements during anaesthesia classified by number of
rs7967354-G and rs11045995-G alleles. Subjects with the homozygous genotype GGþGG in both rs7967354 and rs11045995 (minor allele is G
in both variants) needed significantly less rocuronium during anaesthesia than subjects with other genotypes. The same individuals are
highlighted in blue in Fig. 2a. GWAS, genome-wide association study; SNP, single-nucleotide polymorphism.
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Table 3 Linear regression model with statistically significant
clinical variables and statistically significant clinical variables
and genetic variants with a dose-altering effect. The tested









Age (yr) e0.004 <0.001 e0.006 e0.003
BMI e0.029 <0.001 e0.032 e0.025
ASA physical status 1 0.088 0.019 0.014 0.16
ASA physical status 2 0.06 0.009 0.015 0.10
Propofol
(mg kg1 min1)
2.0 <0.001 1.3 2.7
Adjusted R2¼0.35
Clinical variables and genetic variants
Age (yr) e0.005 <0.001 e0.006 e0.003
BMI e0.028 <0.001 e0.032 e0.025
ASA physical status 1 0.099 <0.001 0.025 0.17
ASA physical status 2 0.075 0.008 0.031 0.12
Propofol
(mg kg1 min1)
1.9 <0.001 1.2 2.6
rs7967354 e0.043 0.001 e0.069 e0.017
rs11045995 e0.090 <0.001 e0.12 e0.062
Adjusted R2¼0.41
CI, confidence interval.
SLCO1A2 and rocuronium dose requirements - 953Supplementary Fig. 2a and b. Based on the genetic recombi-
nation patterns and the FINEMAP tool, the most likely sce-
nario is that two SNPs are needed to explain the association.






















Fig 2. Manhattan plot showing the elog10 P-values of all 653 034 SNPs
positions. The results highlight one genome-wide significant locus o
corner of the image shows the deviation of the observed from the
GWAS, genome-wide association study; SNP, single-nucleotide polymoallele G; MAF¼0.22) and rs11045995 (P¼1.4e10; b¼e0.147 for
allele G; MAF¼0.18), both located in gene SLCO1A2 and in
moderate linkage disequilibrium (LD) with each other
(r2¼0.26). The minor alleles of both variants (rs7967354-G and
rs11045995-G) are associated with decreased rocuronium
requirements.
Patients with two minor alleles (G/G) of the variant
rs7967354 needed significantly less rocuronium during anaes-
thesia (n¼47; median dose rate: 6.1 mg kg1 min1; IQR: 5.5e7.5)
compared with patients with G/A genotype (n¼310; median
dose rate: 7.7 mg kg1 min1; IQR: 6.4e9.5) and A/A genotype
(n¼561; median dose rate: 8.2 mg kg1 min1; IQR: 6.3e9.1)
(Fig. 1b) in KruskaleWallis testing (P<0.001). Similarly, patients
with rs11045995G/G genotypeneeded significantly lower doses
of rocuronium during anaesthesia (n¼37; median dose rate: 6.3
mg kg1min1; IQR: 5.6e7.0; P<0.001) than the patientswith G/A
(n¼254;mediandose rate: 7.5mgkg1min1; IQR: 6.3e9.1) andA/
A genotypes (n¼627; median dose rate: 8.3 mg kg1 min1; IQR:
6.8e10.1) (Fig. 1c). We also found that patients with two minor
alleles in both dose-altering variants (rs7967354-GG þ
rs11045995-GG; n¼19; median dose rate: 5.9 [IQR: 5.4e6.5] mg
kg1 min1) needed even less rocuronium during anaesthesia
than with other genotype combinations in the KruskaleWallis
test (Fig. 1a and d; Supplementary Tables 1 and 2).
The final linear regression model included both the clinical
variables and the two lead SNPs rs7967354 and rs11045995
(Table 3). The variables in the model accounted for 41% of the
variability (adjusted R2) in the rocuronium dose. In this
multivariate analysis, age (P<0.001), BMI (P<0.001), ASA 1 vs
ASA 3 (P¼0.008), ASA 2 vs ASA 3 (P¼0.001), dose of propofol
(P<0.001), rs7967354 (P¼0.001), and rs11045995 (P<0.001)
remained significant at P<0.05. By including the two SNPs inosome
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Table 4 Dose-altering variants found in this genome-wide association analysis.
Chr SNP Gene Minor
allele
MAF b P-value SNP is r2 rs7967354 r2 rs11045995
12 rs7967354 SLCO1A2 G 0.22 e0.1425 5.302e11 Intron variant 1 0.261516




12 rs875234 SLCO1A2 G 0.22 e0.14 1.129e10 30 UTR variant 0.996919 0.260478
12 rs11045995 SLCO1A2 G 0.18 e0.1473 1.416e10 Intron variant 0.261516 1
12 rs10743413 SLCO1A2 G 0.20 e0.1424 2.516e10 Intron variant 0.233591 0.873469
12 rs10841798 SLCO1A2 C 0.18 e0.1417 6.672e10 Intron variant 0.259925 0.982672
12 rs10770800 SLCO1A2 G 0.18 e0.1399 1.228e9 Intron variant 0.266367 0.98603
12 rs10841782 SLCO1A2 A 0.08 e0.1757 8.452e8 Intron variant 0.322123 0.316403
Chr, chromosome; MAF, minor allele frequency in the study sample; r2 squared correlation coefficient measure for linkage disequilibrium, range 0e1;
SNP, single-nucleotide polymorphism.
954 - Ahlstr€om et al.the model, the proportion of the variance explained increased
by 4 percentage points.
As both rs7967354 and rs11045995 are located in the
intronic regions of SLCO1A2, we analysed the region further
using imputed genome data, and FINEMAP and FUMA pro-
grams, to locate other variants possibly driving the association
signal. On the imputed data, FINEMAP gives a probability of
74% to one causal variant and 26% for two causal variants.
Assuming one causal variant, the 95% credible set (the set of
variants containing the causal variant with 95% probability)
contains 20 variants (Supplementary Table 3). Assuming two
causal variants, the lead variants are rs7967354 and
rs10743413 (the latter of which is highly correlated with
rs11045995; r2¼0.88), and the two credible sets contain,
respectively, 13 and 5 variants with probability over 1% of
being causal (Supplementary Table 4). FINEMAP estimates that
the SLCO1A2 region explains 3.75% of the variance of the
phenotype (95% credible interval: 1.77e6.29%).
Next, we performed FUMA analysis to check whether the
most likely causal variants were associated with tissue-
specific changes in the expression level of SLCO1A2 or other
genes. For the 20 potentially causal variants, FUMA analysis
detected 39 expression quantitative trait loci (eQTL) for four
genes at a false discovery rate of 5% (Supplementary Table 5).
For SLCO1A2, three variants were eQTL in the brain and three
in the cerebellum. Other eQTL were found for the gene RECQL
(expression measured in blood), PYROXD1 (in blood), and
C12orf39 (in lymphocytes and in blood). Plots for tissue-wide
expression results for rs7967354 and rs11045995 are in
Supplementary Fig. 3a and b.Discussion
We explored clinical and genetic factors explaining variation
in rocuronium requirement during surgery for breast cancer in
918 women. We showed that a locus containing gene SLCO1A2
affects the dose rate needed for maintaining adequate
neuromuscular block. Of the clinical variables examined, age,
BMI, total dose of propofol, and ASA class were associated with
the rocuronium dose. Combined, these factors explained 41%
of the dose rate variation. Our study provides further confir-
mation that neither CYP2D6 nor CYP3A4 plays a role in
determining rocuronium requirements.
The median rocuronium dose used is in line with previous
reports.30,31 In our study, advanced age,12 lower BMI, andhigher ASA class decreased the amount of rocuronium
needed. Previous reports on the effect of BMI on rocuronium
requirements are conflicting.32,33 Our patients weremedicated
according to their actual body weight, which might explain
why lower BMI decreased rocuronium requirements. We
observed that higher propofol doses were associated with
increased need for rocuronium, whereas some previous
studies suggested that propofol would have muscle-relaxing
effects,34 reducing the required dose of neuromuscular
blockers.35 However, the designs of these studies were very
different from ours. There are no previous linear regression
models evaluating rocuronium needs during propofol
anaesthesia.
Our GWAS identified one genome-wide significant associ-
ation peak, on chromosome 12, in and around the SLCO1A2
gene, which encodes the OATP1A2. The signal was best
explained by two lead SNPs, rs7967354 and rs11045995. Higher
numbers of the minor alleles of these SNPs were associated
with a lesser need for rocuronium. The biggest variation in
rocuronium dosage was observed when we compared partic-
ipants homozygous for both rs7967354 and rs11045995 minor
alleles (G) with those homozygous for the major alleles (A)
(Fig. 1a and d; Supplementary Tables 1 and 2).
Organic anion transporters are cellular transmembrane
proteins, important in the distribution, metabolism, and
excretion of various drugs and expressed in pharmacokineti-
cally important organs, such as liver, kidney, and intestine.36
Based on immunohistochemical staining, OATP1A2 trans-
porters are located in cholangiocytes, where they have an
important role in excretion of drugs into the bile.37 As
rocuronium is a known substrate of OATP1A236 and is mainly
excreted unchanged in the urine (10e25%) and bile (>70%),1,2
the role of OATPs in its excretion is of interest.
A study with Slco1a/1be/e knockout mice showed that lack
of functioning OATP1A2 leads to accumulation of the sub-
strates of this transporter in plasma.38 Previous studies also
indicate that OATPs are a target for drug interactions.
Expression of OATPs, especially OATP-A, were significantly
increased in patients treated with carbamazepine.39 Carba-
mazepine use is known to increase the required rocuronium
dosage.40 Our results suggest that this would be attributable to
induction of OATP1A2 rather than of CYP3A4.
Few previous studies have addressed the pharmacoge-
netics of rocuronium. A candidate gene study based on only 30
patients, by Costa and colleagues,41 showed evidence of
SLCO1A2 and rocuronium dose requirements - 955association between a variant e189_188InsA (rs3834939),
located in the promoter region of the SLCO1A2 gene, and
reduced clearance of rocuronium. Neither this SNP rs3834939
(P¼0.000026 in our study) nor the other variants tested by
Costa and colleagues were amongst the SNPs showing
genome-wide significant evidence of association (a standard
threshold of genome-wide statistical significance is P<5 
108).
The other two earlier rocuronium studies were also
candidate gene studies, analysing only a few variants in small
patient samples. Based on a sample of 105 Chinese patients,
Qi and colleagues42 reported that SNPs rs12720464 and
rs1055302 in the ABCB1 gene, coding for an ATP-dependent
drug efflux pump, associate with prolonged spontaneous re-
covery after a single dose of rocuronium. In the study of Mei
and colleagues,43 another ABCB1 SNP (rs1128503) and an SNP
(rs2306283) in the OATP1B1 transporter gene SLCO1B1 showed
association with the clinical action time of rocuronium in 200
patients. Our data do not provide support for the ABCB1
findings, whilst several variants within the SLCO1B1 gene,
located right next to SLCO1A2, show almost genome-wide
significant evidence of association in our study
(Supplementary Fig. 2a). Further analyses showed that these
SNPs were not independent from our SLCO1A2 lead variants
(data not shown).
The top SNPs in our study, rs7967354 and rs11045995, and
the variants in high LD with them, are located in non-coding
parts of the gene. The intronic rs7967354 is in high LD with
SNPs rs4149005 (non-coding exon transcript variant) and
rs875234 (30 UTR variant). Our extensive eQTL analyses suggest
that a possible mechanism for the genotypeerocuronium dose
association is tissue-specific gene expression regulation. As
OATP1A2 has a role in excretion of rocuronium into bile,6
changes in the expression of SLCO1A2 caused by poly-
morphisms in the genemight prolong the effect of rocuronium
by reducing clearance.
One unexplored option to explain variation in rocuronium
dose requirement is that of inter-individual differences in
neuromuscular junctions. Here, we can only speculate on the
possibility of some underlying variation in neuromuscular
junction in otherwise healthy patients that could explain the
variation in dose needs. Interestingly, SLCO1A2 is highly
expressed in neural tissues, including peripheral nerve tis-
sue, and our eQTL analyses suggested that the lead variants
affect the SLCO1A2 expression level in the brain. It is
tempting to speculate that neural tissue also plays a
role in the impact of SLCO1A2 variants on rocuronium
requirements.
Our study has some limitations. Creatinine or creatinine
clearance values were not available to assess kidney function.
However, patients with clinically relevant kidney failure were
excluded from the study. Although the study cohort is the
largest thus far examined for pharmacogenetic data suitable
for rocuronium studies, it is small for the GWAS approach,
which usually requires thousands of participants. As our re-
sults are based on only 918 participants, all female, it is likely
that some of the more subtle genetic effects remain
undetected.
Our study suggests that genetic variation in the gene
SLCO1A2, encoding OATP1A2, is significantly associated with
differences in rocuronium requirements. Our discovery offers
one explanation for inter-individual differences in the dura-
tion of action of rocuronium. This variation was estimated to
account for 4% of the variability in rocuronium dose. The mostlikely underlying mechanism is altered uptake of rocuronium
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